Citigroup
CNSP icon

Citigroup’s CNS Pharmaceuticals CNSP Stock Holding History

Citigroup’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2 Buy
+1
New +$4 ﹤0.01% 5825
2025
Q4 		– Sell
-2
Closed -$18 – 6124
2025
Q3 		$18 Buy
+2
New +$16 ﹤0.01% 5908
2022
Q3 		– Hold
0
– -$4K – 5887
2022
Q2 		– Hold
0
– – – 5668

Other funds holding CNSP

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Citigroup's CNSP Position: Q1 2026 in Review

Citigroup opened a new position in CNS Pharmaceuticals (CNSP) in Q1 2026: 1 share worth $2. The stake represents ﹤0.01% of the portfolio and ranks #5825 among its holdings. This is a return to the name: Citigroup previously reported a position in CNSP as recently as Q3 2025.

Citigroup first reported a position in CNSP in Q3 2025 and has held it in 2 quarters since. The position peaked at $18 in Q3 2025. 12 funds tracked by Wall St. Rank hold CNSP as of Q1 2026.

  • Citigroup held 1 share of CNS Pharmaceuticals worth $2 as of Q1 2026.
  • CNS Pharmaceuticals was a new Citigroup position in Q1 2026.
  • CNS Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5825 holding.
  • Citigroup first reported a position in CNS Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • Citigroup's CNS Pharmaceuticals position peaked at $18 in Q3 2025.
  • 12 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.